← Back to Screener
SELLAS Life Sciences Group, Inc. Common Stock (SLS)
Price$4.99
Favorite Metrics
Price vs S&P 500 (26W)164.55%
Price vs S&P 500 (4W)0.17%
Market Capitalization$937.42M
All Metrics
Book Value / Share (Quarterly)$0.46
P/TBV (Annual)4.32x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.19
Price vs S&P 500 (YTD)34.32%
Gross Margin (TTM)93.10%
Net Profit Margin (TTM)-736.21%
EPS (TTM)$-0.25
10-Day Avg Trading Volume4.17M
EPS Excl Extra (TTM)$-0.25
EPS (Annual)$-0.51
ROI (Annual)-327.52%
Gross Margin (Annual)90.00%
Net Profit Margin (5Y Avg)-1197.32%
Cash / Share (Quarterly)$0.47
ROA (Last FY)-159.53%
EBITD / Share (TTM)$-0.26
ROE (5Y Avg)-331.50%
Operating Margin (TTM)-730.69%
Cash Flow / Share (Annual)$-0.19
P/B Ratio13.23x
P/B Ratio (Quarterly)7.58x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)298.49x
Net Interest Coverage (TTM)-238.57x
ROA (TTM)-54.50%
EPS Incl Extra (Annual)$-0.51
Current Ratio (Annual)10.72x
Quick Ratio (Quarterly)10.28x
3-Month Avg Trading Volume8.23M
52-Week Price Return307.81%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.28
P/S Ratio (Annual)937.42x
Asset Turnover (Annual)0.05x
52-Week High$6.14
Operating Margin (5Y Avg)-1281.81%
EPS Excl Extra (Annual)$-0.51
Tangible BV CAGR (5Y)52.96%
26-Week Price Return173.30%
Quick Ratio (Annual)10.28x
13-Week Price Return27.01%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.72x
Enterprise Value$865.628
Asset Turnover (TTM)0.09x
Book Value / Share Growth (5Y)-17.33%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4130.00%
Cash / Share (Annual)$0.47
3-Month Return Std Dev90.91%
Net Income / Employee (TTM)$-2
ROE (Last FY)-327.52%
Net Interest Coverage (Annual)-532.75x
EPS Basic Excl Extra (Annual)$-0.51
Receivables Turnover (TTM)4.46x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.25
Receivables Turnover (Annual)13.45x
ROI (TTM)-63.06%
P/S Ratio (TTM)323.25x
Pretax Margin (5Y Avg)-1213.64%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.28
Price vs S&P 500 (52W)272.72%
Year-to-Date Return38.46%
5-Day Price Return9.66%
EPS Normalized (Annual)$-0.51
ROA (5Y Avg)-214.47%
Net Profit Margin (Annual)-4130.00%
Month-to-Date Return23.40%
Cash Flow / Share (TTM)$-0.36
EBITD / Share (Annual)$-0.51
Operating Margin (Annual)-4195.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-331.50%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.25
P/TBV (Quarterly)4.31x
P/B Ratio (Annual)7.58x
Pretax Margin (TTM)-736.21%
Book Value / Share (Annual)$0.46
Price vs S&P 500 (13W)24.14%
Beta2.35x
Revenue / Share (TTM)$0.00
ROE (TTM)-63.06%
52-Week Low$1.26
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
SLSSELLAS Life Sciences Group, Inc. Common Stock | 323.25x | — | 93.10% | — | $4.99 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing immunotherapies and targeted cancer treatments. The company's pipeline includes galinpepimut-S, a peptide immunotherapy targeting the WT1 antigen, and GFH009, a selective CDK9 inhibitor. Both candidates address multiple cancer indications through distinct mechanisms of action.